2. Academic Validation
  3. DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome

DNA-Encoded Library-Derived DDR1 Inhibitor Prevents Fibrosis and Renal Function Loss in a Genetic Mouse Model of Alport Syndrome

  • ACS Chem Biol. 2019 Jan 18;14(1):37-49. doi: 10.1021/acschembio.8b00866.
Hans Richter 1,  Alexander L Satz 1,  Marc Bedoucha 1,  Bernd Buettelmann 1,  Ann C Petersen 1,  Anja Harmeier 1,  Ricardo Hermosilla 1,  Remo Hochstrasser 1,  Dominique Burger 1,  Bernard Gsell 1,  Rodolfo Gasser 1,  Sylwia Huber 1,  Melanie N Hug 1,  Buelent Kocer 1,  Bernd Kuhn 1,  Martin Ritter 1,  Markus G Rudolph 1,  Franziska Weibel 1 2,  Judith Molina-David 3 4,  Jin-Ju Kim 3 4,  Javier Varona Santos 3 4,  Martine Stihle 1,  Guy J Georges 5,  R Daniel Bonfil 6,  Rafael Fridman 7,  Sabine Uhles 1,  Solange Moll 8,  Christian Faul 9,  Alessia Fornoni 3,  Marco Prunotto 1 10
Affiliations

Affiliations

  • 1 Roche Pharma Research and Early Development, Roche Innovation Center , Basel 4070 , Switzerland.
  • 2 Ridgeline Therapeutics GmbH , Basel 4070 , Switzerland.
  • 3 Katz Family Division of Nephrology and Hypertension , University of Miami Miller School of Medicine , Miami , Florida 33136 , United States.
  • 4 Peggy and Harold Katz Family Drug Discovery Center , University of Miami Miller School of Medicine , Miami , Florida 33136 , United States.
  • 5 Roche Pharma Research and Early Development, Roche Innovation Center , Munich 82377 , Germany.
  • 6 Department of Pathology, College of Medical Sciences , Nova Southeastern University , Fort Lauderdale , Florida 33328 , United States.
  • 7 Department of Pathology , Wayne State University , Detroit , Michigan 48202 , United States.
  • 8 University Hospital of Geneva , 1205 Geneva , Switzerland.
  • 9 University of Alabama at Birmingham , Birmingham , Alabama 35294, United States.
  • 10 Office of Innovation, Immunology, Infectious Diseases & Ophthalmology (I2O) , Roche and Genentech Late Stage Development , Basel 4070 , Switzerland.
PMID: 30452219 DOI: 10.1021/acschembio.8b00866
Abstract

The importance of Discoidin Domain Receptor 1 (DDR1) in renal fibrosis has been shown via gene knockout and use of antisense oligonucleotides; however, these techniques act via a reduction of DDR1 protein, while we prove the therapeutic potential of inhibiting DDR1 phosphorylation with a small molecule. To date, efforts to generate a selective small-molecule to specifically modulate the activity of DDR1 in an in vivo model have been unsuccessful. We performed parallel DNA encoded library screens against DDR1 and DDR2, and discovered a chemical series that is highly selective for DDR1 over DDR2. Structure-guided optimization efforts yielded the potent DDR1 Inhibitor 2.45, which possesses excellent kinome selectivity (including 64-fold selectivity over DDR2 in a biochemical assay), a clean in vitro safety profile, and favorable pharmacokinetic and physicochemical properties. As desired, compound 2.45 modulates DDR1 phosphorylation in vitro as well as prevents collagen-induced activation of renal epithelial cells expressing DDR1. Compound 2.45 preserves renal function and reduces tissue damage in Col4a3-/- mice (the preclinical mouse model of Alport syndrome) when employing a therapeutic dosing regime, indicating the real therapeutic value of selectively inhibiting DDR1 phosphorylation in vivo. Our results may have wider significance as Col4a3-/- mice also represent a model for chronic kidney disease, a disease which affects 10% of the global population.

Figures
Products